Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases

Maurizio Benucci,1 Arianna Damiani,1 Francesca Li Gobbi,1 Francesca Bandinelli,1 Maria Infantino,2 Valentina Grossi,2 Mariangela Manfredi,2 Guillaume Noguier,3 Francesca Meacci2 1Rheumatology Unit, 2Immunology and Allergology Laboratory Unit, USL-Toscana Centro, Hospital S. Giovanni di Dio, Florence...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Benucci M, Damiani A, Li Gobbi F, Bandinelli F, Infantino M, Grossi V, Manfredi M, Noguier G, Meacci F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Anti-drug antibodies HLA haplotypes rheumatic diseases Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/26bf5161f3b34a8aaff294f178605679
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:26bf5161f3b34a8aaff294f178605679
record_format	dspace
spelling	oai:doaj.org-article:26bf5161f3b34a8aaff294f1786056792021-12-02T00:11:07ZCorrelation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases1177-5491https://doaj.org/article/26bf5161f3b34a8aaff294f1786056792018-01-01T00:00:00Zhttps://www.dovepress.com/correlation-between-hla-haplotypes-and-the-development-of-antidrug-ant-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Maurizio Benucci,1 Arianna Damiani,1 Francesca Li Gobbi,1 Francesca Bandinelli,1 Maria Infantino,2 Valentina Grossi,2 Mariangela Manfredi,2 Guillaume Noguier,3 Francesca Meacci2 1Rheumatology Unit, 2Immunology and Allergology Laboratory Unit, USL-Toscana Centro, Hospital S. Giovanni di Dio, Florence, Italy; 3Theradiag, Croissy Beaubourg, France Introduction: The aim of this study was to investigate the correlation between human leukocyte antigen (HLA) haplotypes and the development of antidrug antibodies (ADAs) in a cohort of patients with rheumatic diseases.Patients and methods: We evaluated the presence of ADAs in 248 patients with inflammatory rheumatic diseases after 6 months of treatment with anti-TNF drugs: 26 patients were treated with infliximab (IFX; three with rheumatoid arthritis [RA], 13 with ankylosing spondylitis [AS], 10 with psoriatic arthritis [PsA]); 83 treated with adalimumab (ADA; 24 with RA, 36 with AS, 23 with PsA); 88 treated with etanercept (ETA; 35 with RA, 27 with AS, 26 with PsA); 32 treated with certolizumab (CERT; 25 with RA, two with AS, five with PsA); and 19 treated with golimumab (GOL; three with RA, seven with AS, nine with PsA). Serum drug and ADA levels were determined using Lisa-Tracker Duo, the ADA-positive samples underwent an inhibition test, and the true-positive samples underwent genetic HLA typing. To have a homogeneous control population, we also performed genetic HLA typing of 11 ADA-negative patients.Results: After inhibition test, the frequency of ADAs was 2/26 patients treated with IFX (7.69%), 4/83 treated with ADA (4.81%), 0/88 treated with ETA (0%), 4/32 treated with CERT (12.5%), and 1/19 treated with GOL (5.26%). The frequency of HLA alleles in the examined patients was HLA-DRβ-11 0.636, HLA-DQ-03 0.636, and HLA-DQ-05 0.727. The estimated relative risks between the ADA-positive patients and the ADA-negative patients were HLA-DRβ-11 2.528 (95% CI 0.336–19.036), HLA-DQ-03 1.750 (95% CI 0.289–10.581), and HLA-DQ-05 2.424 (95% CI 0.308–15.449). Conclusion: This is the first study that shows an association between HLA and genetic factors associated with the occurrence of ADAs in patients with rheumatic diseases, but the number of samples is too small to draw any definite conclusion. Keywords: antidrug antibodies, HLA haplotypes, rheumatic diseases Benucci MDamiani ALi Gobbi FBandinelli FInfantino MGrossi VManfredi MNoguier GMeacci FDove Medical PressarticleAnti-drug antibodiesHLA haplotypesrheumatic diseasesMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 12, Pp 37-41 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Anti-drug antibodies HLA haplotypes rheumatic diseases Medicine (General) R5-920
spellingShingle	Anti-drug antibodies HLA haplotypes rheumatic diseases Medicine (General) R5-920 Benucci M Damiani A Li Gobbi F Bandinelli F Infantino M Grossi V Manfredi M Noguier G Meacci F Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases
description	Maurizio Benucci,1 Arianna Damiani,1 Francesca Li Gobbi,1 Francesca Bandinelli,1 Maria Infantino,2 Valentina Grossi,2 Mariangela Manfredi,2 Guillaume Noguier,3 Francesca Meacci2 1Rheumatology Unit, 2Immunology and Allergology Laboratory Unit, USL-Toscana Centro, Hospital S. Giovanni di Dio, Florence, Italy; 3Theradiag, Croissy Beaubourg, France Introduction: The aim of this study was to investigate the correlation between human leukocyte antigen (HLA) haplotypes and the development of antidrug antibodies (ADAs) in a cohort of patients with rheumatic diseases.Patients and methods: We evaluated the presence of ADAs in 248 patients with inflammatory rheumatic diseases after 6 months of treatment with anti-TNF drugs: 26 patients were treated with infliximab (IFX; three with rheumatoid arthritis [RA], 13 with ankylosing spondylitis [AS], 10 with psoriatic arthritis [PsA]); 83 treated with adalimumab (ADA; 24 with RA, 36 with AS, 23 with PsA); 88 treated with etanercept (ETA; 35 with RA, 27 with AS, 26 with PsA); 32 treated with certolizumab (CERT; 25 with RA, two with AS, five with PsA); and 19 treated with golimumab (GOL; three with RA, seven with AS, nine with PsA). Serum drug and ADA levels were determined using Lisa-Tracker Duo, the ADA-positive samples underwent an inhibition test, and the true-positive samples underwent genetic HLA typing. To have a homogeneous control population, we also performed genetic HLA typing of 11 ADA-negative patients.Results: After inhibition test, the frequency of ADAs was 2/26 patients treated with IFX (7.69%), 4/83 treated with ADA (4.81%), 0/88 treated with ETA (0%), 4/32 treated with CERT (12.5%), and 1/19 treated with GOL (5.26%). The frequency of HLA alleles in the examined patients was HLA-DRβ-11 0.636, HLA-DQ-03 0.636, and HLA-DQ-05 0.727. The estimated relative risks between the ADA-positive patients and the ADA-negative patients were HLA-DRβ-11 2.528 (95% CI 0.336–19.036), HLA-DQ-03 1.750 (95% CI 0.289–10.581), and HLA-DQ-05 2.424 (95% CI 0.308–15.449). Conclusion: This is the first study that shows an association between HLA and genetic factors associated with the occurrence of ADAs in patients with rheumatic diseases, but the number of samples is too small to draw any definite conclusion. Keywords: antidrug antibodies, HLA haplotypes, rheumatic diseases
format	article
author	Benucci M Damiani A Li Gobbi F Bandinelli F Infantino M Grossi V Manfredi M Noguier G Meacci F
author_facet	Benucci M Damiani A Li Gobbi F Bandinelli F Infantino M Grossi V Manfredi M Noguier G Meacci F
author_sort	Benucci M
title	Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases
title_short	Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases
title_full	Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases
title_fullStr	Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases
title_full_unstemmed	Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases
title_sort	correlation between hla haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/26bf5161f3b34a8aaff294f178605679
work_keys_str_mv	AT benuccim correlationbetweenhlahaplotypesandthedevelopmentofantidrugantibodiesinacohortofpatientswithrheumaticdiseases AT damiania correlationbetweenhlahaplotypesandthedevelopmentofantidrugantibodiesinacohortofpatientswithrheumaticdiseases AT ligobbif correlationbetweenhlahaplotypesandthedevelopmentofantidrugantibodiesinacohortofpatientswithrheumaticdiseases AT bandinellif correlationbetweenhlahaplotypesandthedevelopmentofantidrugantibodiesinacohortofpatientswithrheumaticdiseases AT infantinom correlationbetweenhlahaplotypesandthedevelopmentofantidrugantibodiesinacohortofpatientswithrheumaticdiseases AT grossiv correlationbetweenhlahaplotypesandthedevelopmentofantidrugantibodiesinacohortofpatientswithrheumaticdiseases AT manfredim correlationbetweenhlahaplotypesandthedevelopmentofantidrugantibodiesinacohortofpatientswithrheumaticdiseases AT noguierg correlationbetweenhlahaplotypesandthedevelopmentofantidrugantibodiesinacohortofpatientswithrheumaticdiseases AT meaccif correlationbetweenhlahaplotypesandthedevelopmentofantidrugantibodiesinacohortofpatientswithrheumaticdiseases
_version_	1718403851922440192

Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases

Ejemplares similares